The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
Innovative research has helped doctors learn more about how cancer cells grow and why it’s a bit different in every person. This has led to the development of drugs that target specific molecules that ...
Patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) had a high response rate and prolonged event-free survival (EFS) following treatment with an investigational FLT3 inhibitor and ...
After dose escalation, 120 mg gilteritinib once daily was chosen for further study. There were 58 participants evaluable for response at this dose, 36 of whom harbored FLT3 mutations. For participants ...
The US Food and Drug Administration today approved quizartinib (Vanflyta) for adults with acute myeloid leukemia (AML) that carries the FLT3-ITD genetic mutation. The FDA also approved the LeukoStrat ...
Credit: Daiichi Sankyo. Vanflyta is expected to be available in the coming weeks. The Food and Drug Administration (FDA) has approved Vanflyta ® (quizartinib) in combination with standard cytarabine ...
Note: This article has been updated to reflect the correct revised PDUFA date. FDA has added 3 months to the review timeline for quizartinib, an investigational therapy for the treatment of adult ...
Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper infrastructure, while treatment decisions are based on intensive vs ...
Treatment of older patients with AML involves complex decisions taking into consideration age, fitness, treatment tolerability, quality of life, and social support. Increased treatment options have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results